Although mature management and treatment on DN have been established in these years like blood glucose monitoring and application of RAS inhibitors or sodium-glucose cotransporter 2 inhibitors, a more effective strategy should be explored to stop DN progression [80]. This evidence concerns the gene SLC5A2 and liver dysplastic nodule.